Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1412748 | 0.94 | KDM1A (0.41) | KDM1A | |
| SCHEMBL17634062 | 0.90 | KDM1A (0.33) | KDM1A | |
| SCHEMBL868982 | 0.83 | KDM1A (0.36) | KDM1A | |
| SCHEMBL13739295 | 0.77 | MAPT (0.35) | — | |
| SCHEMBL8750616 | 0.75 | — | — | |
| SCHEMBL28364603 | 0.72 | — | — | |
| SCHEMBL6536235 | 0.72 | — | — | |
| SCHEMBL30540267 | 0.72 | — | — | |
| SCHEMBL18652628 | 0.72 | — | — | |
| SCHEMBL8518192 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113677364-B | Pharmaceutical compositions comprising anti-191P 4D12 antibody drug conjugates and methods of use thereof | 艾更斯司股份有限公司 | 2024-07-05 | — | — | CN | disclosed |
| EP-4378482-A2 | DOSING REGIMENS FOR ANTI-CD30 VC-PAB-MMAE ANTIBODY DRUG-CONJUGATES | Seagen Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| US-20240139275-A1 | WEEKLY DOSING REGIMENS FOR ANTI-CD30 VC-PAB-MMAE ANTIBODY DRUG-CONJUGATES | SEAGEN INC (US) | 2024-05-02 | — | — | US | disclosed |
| US-20240131176-A1 | SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY | SEAGEN INC (US) | 2024-04-25 | — | — | US | disclosed |
| US-20240043556-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | AGENSYS, INC. (US) | 2024-02-08 | — | — | US | disclosed |
| EP-3545969-B1 | DOSING REGIMENS FOR ANTI-CD30 VC-PAB-MMAE ANTIBODY DRUG-CONJUGATES | SEAGEN INC (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230346968-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS, INC. (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230270871-A1 | MARKERS FOR USE IN METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) | AGENSYS, INC. (US) | 2023-08-31 | — | — | US | disclosed |
| CN-116209464-A | Markers for use in methods of treating cancer with Antibody Drug Conjugates (ADCs) | 艾更斯司股份有限公司 | 2023-06-02 | — | — | CN | disclosed |
| EP-4168039-A1 | MARKERS FOR USE IN METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) | Agensys, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| WO-2011050242-A1 | ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011038159-A2 | DR5 LIGAND DRUG CONJUGATES | SEATTLE GENETICS, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| US-20110070248-A1 | DR5 LIGAND DRUG CONJUGATES | SEATTLE GENETICS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20100330107-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 24P4C12 PROTEINS | AGENSYS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| WO-2010111018-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 24P4C12 PROTEINS | AGENSYS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| US-20100215671-A1 | Combination Therapy With Antibody-Drug Conjugates | SEAGEN INC. | 2010-08-26 | — | — | US | disclosed |
| EP-2211885-A1 | COMBINATION THERAPY WITH ANTIBODY-DRUG CONJUGATES | Seattle Genetics, Inc. (US) | 2010-08-04 | — | — | EP | disclosed |
| WO-2010081004-A1 | WEEKLY DOSING REGIMENS FOR ANTI-CD30 VC-PAB-MMAE ANTIBODY DRUG-CONJUGATES | SEATTLE GENETICS, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| US-20090149400-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| WO-2009048967-A1 | COMBINATION THERAPY WITH ANTIBODY-DRUG CONJUGATES | SEATTLE GENETICS, INC. (US) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240131176-A1 | SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY | MTOR, RICTOR, PIK3R5 | KDM1A 3216/4885 |
| US-20240043556-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | LGALS3BP, PABPC4, PA2G4 | KDM1A 2912/4885 |
| US-20100330107-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 24P4C12 PROTEINS | CD2BP2, IGSF11, PA2G4 | KDM1A 3382/4885 |
| US-20110070248-A1 | DR5 LIGAND DRUG CONJUGATES | TNFRSF1A, TNFSF10, TNFRSF9 | KDM1A 4614/4885 |
| US-20090149400-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | CCNY, CCNO, CCNB3 | KDM1A 3120/4885 |
| US-20240139275-A1 | WEEKLY DOSING REGIMENS FOR ANTI-CD30 VC-PAB-MMAE ANTIBODY DRUG-CONJUGATES | CD44, PABPC1, CD47 | KDM1A 1433/4885 |
| US-20100215671-A1 | Combination Therapy With Antibody-Drug Conjugates | BCL6, BCL3, CD22 | KDM1A 2862/4885 |
| US-20230270871-A1 | MARKERS FOR USE IN METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) | CD44, CD2BP2, EPCAM | KDM1A 2640/4885 |
| US-20230346968-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | IGSF11, CD2BP2, PA2G4 | KDM1A 2640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.